Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan
FDA’s regulatory timeline for reviewing the two pulmonary arterial hypertension medications may fall neck and neck.
More from Archive
More from Pink Sheet
The European Medicines Agency is this week expected issue opinions on whether the European Commission should grant EU marketing authorization for 19 new products.
Miguel Forte, CEO of Kiji Therapeutics, tells the Pink Sheet why he is confident in the future of gene therapies, despite the global “turmoil” that is impacting investment in the industry and changes to the EU and US regulatory landscapes.
Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.